Implementation of dapagliflozin as adjunctive therapy in type 1 diabetes: a single centre real‐world experience

Corresponding Author

Cambridge University Hospitals NHS Foundation Trust, Wolfson Diabetes and Endocrine Clinic, Cambridge, UK

Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK

Corresponding Author:

Charlotte Boughton, MRCP, PhD, University of Cambridge Metabolic Research Laboratories , Level 4, Wellcome Trust-MRC Institute of Metabolic Science, Box 289, Addenbrooke’s Hospital, Hills Rd, Cambridge CB2 0QQ, UK, tel: +44 1223 769 066; fax:+44 1223 330 598

email: cb2000@medschl.cam.ac.uk

Search for more papers by this author

Comments (0)

No login
gif